Show simple item record

Files in this item


Item metadata

dc.contributor.authorCowton, Vanessa M.
dc.contributor.authorOwsianka, Ania M.
dc.contributor.authorFadda, Valeria
dc.contributor.authorOrtega-Prieto, Ana Maria
dc.contributor.authorCole, Sarah J.
dc.contributor.authorPotter, Jane A.
dc.contributor.authorSkelton, Jessica K.
dc.contributor.authorJeffrey, Nathan
dc.contributor.authorDi Lorenzo, Caterina
dc.contributor.authorDorner, Marcus
dc.contributor.authorTaylor, Garry L.
dc.contributor.authorPatel, Arvind H.
dc.identifier.citationCowton , V M , Owsianka , A M , Fadda , V , Ortega-Prieto , A M , Cole , S J , Potter , J A , Skelton , J K , Jeffrey , N , Di Lorenzo , C , Dorner , M , Taylor , G L & Patel , A H 2021 , ' Development of a structural epitope mimic : an idiotypic approach to HCV vaccine design ' , npj Vaccines , vol. 6 , 7 .
dc.identifier.otherPURE: 272471520
dc.identifier.otherPURE UUID: fd3f7c4b-eb21-4e41-913e-ad5a7b5e7ce6
dc.identifier.otherJisc: 628d02cb0dd842e6bd91a5b31aecc152
dc.identifier.otherpublisher-id: s41541-020-00269-1
dc.identifier.othermanuscript: 269
dc.identifier.otherScopus: 85098939879
dc.identifier.otherORCID: /0000-0001-9486-566X/work/87404738
dc.identifier.otherWOS: 000610367100001
dc.descriptionFunding: This work was supported by Medical Research Council grant MC_UU12014/2 and DPFS Grant MC_EX_G0801770 awarded to AHP, and by a studentship to VF from the Programma Master and Back, Regione Autonoma della Sardegna. This study was supported by funding from a Wellcome Trust New Investigator award to MD (104771/Z/14/Z) and a starting grant from the European Research Council to MD (ERC-StG-2015-637304).en
dc.description.abstractHCV vaccine development is stymied by the high genetic diversity of the virus and the variability of the envelope glycoproteins. One strategy to overcome this is to identify conserved, functionally important regions—such as the epitopes of broadly neutralizing antibodies (bNAbs)—and use these as a basis for structure-based vaccine design. Here, we report an anti-idiotype approach that has generated an antibody that mimics a highly conserved neutralizing epitope on HCV E2. Crucially, a mutagenesis screen was used to identify the antibody, designated B2.1 A, whose binding characteristics to the bNAb AP33 closely resemble those of the original antigen. Protein crystallography confirmed that B2.1 A is a structural mimic of the AP33 epitope. When used as an immunogen B2.1 A induced antibodies that recognized the same epitope and E2 residues as AP33 and most importantly protected against HCV challenge in a mouse model.
dc.relation.ispartofnpj Vaccinesen
dc.rightsCopyright © The Author(s) 2021. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit
dc.subjectQR355 Virologyen
dc.subjectRM Therapeutics. Pharmacologyen
dc.titleDevelopment of a structural epitope mimic : an idiotypic approach to HCV vaccine designen
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews.School of Biologyen
dc.contributor.institutionUniversity of St Andrews.Biomedical Sciences Research Complexen
dc.description.statusPeer revieweden

This item appears in the following Collection(s)

Show simple item record